Training Program in Cancer Pharmacology

描述（由申请人提供）：癌症药理学培训资助。多学科癌症药理学培训计划的目的是为博士生和博士后学生提供宾夕法尼亚大学目前不存在的培训环境。Drs。Blair（项目主任），Penning（项目联合主任）和Assoian（项目联合主任）为发展多阶段癌变分子机制的多学科项目提供了持续的领导。现在，在癌症药理学领域所需的多学科环境中，确实需要类似的持续领导来招聘和培训博士前和博士后科学家。在未来十年中，癌症治疗的重大进展将来自多学科方法，以了解恶性细胞在分子水平上如何工作，并设计新的治疗药物来破坏这些过程。因此，拟议的培训计划将有助于填补目前有资格开发下一代化疗药物的人员短缺。该项目的最终目标是提供从实验室到床边再回来的癌症药理学培训。具体来说，学员将学习如何使用癌症药理学来确定新的靶点，如何合成小分子并针对这些靶点进行测试，如何在I期试验中使用它们，如何将I期研究发展为完整的临床试验，以及如何利用流行病学和药物遗传学来评估疗效并导致新靶点的发现。受训者还将接受具体培训，学习如何将药物效应的定量测量从模型系统的概念证明投射到人体剂量的合理选择中。这些目标将通过提供的课程和教师提供的多学科研究经验来实现。26位具有不同互补专业知识的教师导师分为三个项目：A.药理学发现和发展。B.细胞与分子肿瘤药理学。C.临床肿瘤药理学。受训者将有来自其中两个项目的研究导师。这个项目的导师们作为癌症研究人员有着非常出色的成就记录。他们是首席研究员或项目负责人

DESCRIPTION (provided by applicant): Training Grant in Cancer Pharmacology. The purpose of the multidisciplinary Cancer Pharmacology training program is to provide predoctoral and postdoctoral students with a training environment that does not currently exist at the University of Pennsylvania. Drs. Blair (Program Director), Penning (Program Co-Director) and Assoian (Program Co-Director) have provided the sustained leadership required to develop a multidisciplinary program in molecular mechanisms of multi-stage carcinogenesis. There is now a real need for similar sustained leadership to be applied to the recruitment and training of both predoctoral and postdoctoral scientists in the multidisciplinary environment required for the field of cancer pharmacology. Major advances in the treatment of cancer patients in the next decade will result from multidisciplinary approaches in understanding of how malignant cells work at the molecular level and in designing novel therapeutic agents to disrupt these processes. Therefore, the proposed training program will help fill the current deficit of individuals qualified to develop the next generation of chemotherapeutic agents. The ultimate goal of the program is to provide training in cancer pharmacology that goes from laboratory to bedside and back again. Specifically, trainees will learn how cancer pharmacology can be used to identify new targets, how small molecules are synthesized and tested against these targets, how they are used in Phase I trials, how Phase I studies are developed into full clinical trials, and how epidemiology and pharmacogenetics are utilized to assess efficacy and lead to the discovery of new targets. Trainees will also receive specific training in how to project quantitative measures of drug effect from proof of concept in model systems into the rational selection of dosing in humans. These goals will be accomplished through the courses that are offered and the multidisciplinary research experiences that will be available from the faculty. The 26 faculty mentors with diverse complementary expertise are grouped into three programs: A. Pharmacology Discovery and Development. B. Cell and Molecular Cancer Pharmacology. C. Clinical Cancer Pharmacology. The trainees will have research mentors from two of these programs. The mentors on this proposed program have a very strong record of accomplishment as cancer researchers. They are Principal Investigators or Project Leaders on 68 NIH grants of which 39 (57%) are from NCI (27 RO-1s, 8 PO-1 Projects, 1 PO-1 Scientific Core, 1 P30 Scientific Core, 1 UO-1, 1 T-32). Apart from training grants, 11 of the mentors have NIH-funded (primarily through NCI) collaborative research grants. The mentors serve on Editorial Boards of 23 Journals and two of them are Journal Editors. Over the past 10-years, the mentors have trained 105 predoctoral students and 250 postdoctoral fellows; they currently have 52 predoctoral and 76 postdoctoral trainees in their laboratories. The mentors have clearly demonstrated that they have the scientific expertise and training experience to develop a new multidisciplinary training program in Cancer Pharmacology. Mentors have superb access to different patient populations through their association with 11 NCI-funded clinical programs. Furthermore, one of the mentors is Director of the General Clinical Research Center at the University of Pennsylvania (Dr. FitzGerald) and one is acting Director of the General Clinical Research Center at Children's Hospital of Philadelphia (Dr. Adamson). Both of these mentors have research programs with a focus on translational therapeutics and so they provide another outstanding training resource.